Stockreport

TCR² Therapeutics Announces Pricing of Public Offering of $140.0 Million of Common Stock

TCR2 Therapeutics Inc.  (TCRR) 
Last tcr2 therapeutics inc. earnings: 11/12 07:00 am Check Earnings Report
PDF CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR) (“TCR2” or the “Company”), a clinical-stage immunotherapy company with a pipe [Read more]